Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report
Authors
Keywords
-
Journal
Cardiovascular Diabetology
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-09-03
DOI
10.1186/s12933-022-01607-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dapagliflozin induces vasodilation in resistance-size mesenteric arteries by stimulating smooth muscle cell KV7 ion channels
- (2022) Ahasanul Hasan et al. Heliyon
- Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis
- (2022) Rongjun Zou et al. Cardiovascular Diabetology
- Association of SGLT2 inhibitors with outcomes in Type 2 diabetes with reduced and preserved left ventricular ejection fraction — Analysis from the CVD‐REAL 2 Study
- (2021) Carolyn S. P. Lam et al. DIABETES OBESITY & METABOLISM
- Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo‐controlled, exploratory study
- (2021) Jonas Oldgren et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
- (2021) Andrei C. Sposito et al. Cardiovascular Diabetology
- Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling
- (2021) Yuze Zhang et al. Cardiovascular Diabetology
- Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial
- (2021) Mikkel Jürgens et al. Journal of the American Heart Association
- Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial
- (2021) Gian Pio Sorice et al. Diabetes Therapy
- A Meta-Analysis of the Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure and Preserved Ejection Fraction
- (2021) Ahmad Al-Abdouh et al. AMERICAN JOURNAL OF CARDIOLOGY
- Dapagliflozin alleviates advanced glycation end product induced podocyte injury through AMPK/mTOR mediated autophagy pathway
- (2021) Lei Yang et al. CELLULAR SIGNALLING
- How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?
- (2020) Matthew M.Y. Lee et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium
- (2020) Donato Cappetta et al. PHARMACOLOGICAL RESEARCH
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
- (2019) Aino Latva-Rasku et al. DIABETES CARE
- SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
- (2019) Damilola D. Adingupu et al. Cardiovascular Diabetology
- Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy
- (2019) Anja Schork et al. Cardiovascular Diabetology
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium‐glucose co‐transporter inhibitors: Medications that mimic fasting for cardiovascular prevention
- (2019) Andrea Giaccari DIABETES OBESITY & METABOLISM
- SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus
- (2019) David A. Hess et al. Cell Metabolism
- Type 2 Diabetes Mellitus and Cardiovascular Disease: Genetic and Epigenetic Links
- (2018) Salvatore De Rosa et al. Frontiers in Endocrinology
- Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component?
- (2018) Francesco Prattichizzo et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
- (2016) Giuseppe Daniele et al. DIABETES CARE
- Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males
- (2016) Aurora Merovci et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin
- (2013) Sunder Mudaliar et al. Diabetes Technology & Therapeutics
- Coronary microvascular dysfunction: an update
- (2013) F. Crea et al. EUROPEAN HEART JOURNAL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started